These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of Parkinson's disease : what's on the horizon? Wu SS; Frucht SJ CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in pharmacological therapy of Parkinson's disease. Riederer P; Lange KW; Youdim MB Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Parkinson's disease: present and future. Miller DB; O'Callaghan JP Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818 [TBL] [Abstract][Full Text] [Related]
6. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
7. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. Chen JF Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141 [TBL] [Abstract][Full Text] [Related]
8. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217 [TBL] [Abstract][Full Text] [Related]
9. New treatments for the motor symptoms of Parkinson's disease. Vijverman AC; Fox SH Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological therapy of Parkinson's disease: current options and new avenues. Simola N; Pinna A; Fenu S Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838 [TBL] [Abstract][Full Text] [Related]
12. Rasagiline in the pharmacotherapy of Parkinson's disease--a review. Rascol O Expert Opin Pharmacother; 2005 Oct; 6(12):2061-75. PubMed ID: 16197359 [TBL] [Abstract][Full Text] [Related]
13. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. Bisaglia M; Greggio E; Beltramini M; Bubacco L FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698 [TBL] [Abstract][Full Text] [Related]
14. Novel pharmacological targets for the treatment of Parkinson's disease. Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425 [TBL] [Abstract][Full Text] [Related]
15. The role of dopamine agonists in early Parkinson's disease. Watts RL Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273 [TBL] [Abstract][Full Text] [Related]
16. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No]. Friedman A Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453 [TBL] [Abstract][Full Text] [Related]
17. Drugs used to treat Parkinson's disease, present status and future directions. Abdel-Salam OM CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Hung AY; Schwarzschild MA Neurotherapeutics; 2014 Jan; 11(1):34-46. PubMed ID: 24310604 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease: problems with a progressing disease. Rinne UK J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627 [TBL] [Abstract][Full Text] [Related]
20. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]